Nexalin Technology, Inc. · NASDAQ:NXL
Nexalin Technology — Investor Presentation (January 2023)
21 slides from Nexalin Technology's investor presentation, January 2023
Slide 1: Investor Presentation January 2023
Investor Presentation January 2023
Slide 2: Nexalin Forward Looking Statement
Nexalin Forward Looking Statement This presentation material includes forward-looking statements that reflect our current views with respect to future events. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking sta
Slide 3: Company Snapshot
Company Snapshot Nexalin Technology’s mission is to design and market FDA Class II & III neuro-stimulators for the treatment of: Anxiety – Depression - Insomnia – Dementia – Pain - Addiction 1 existing patent 40+ units in $40MM invested Large addressable $40MM $94B and 5 pending use globally since i
Slide 4: Management – Core Executive Team
Management – Core Executive Team Mark White --- Marilyn Elson --- David Owens M.D. --- President and Chief Executive Officer Chief Financial Officer Chief Medical Officer Mark leads the executive team at Marilyn Elson has been a Certified Dr. David Owens has been with Nexalin Nexalin Technology. Pri
Slide 5: Board of Advisors – Global Strategy and Planning Post IPO
Board of Advisors – Global Strategy and Planning Post IPO John Patrick Claude – Engineering and Product Development (Co-Founder / waveform designer) Mr. John Claude, in conjunction with Dr. Yakov Katsnelson, designed and developed the original tACS waveform that is marketed as Nexalin Technology. Jo
Slide 6: Investment Highlights
Investment Highlights Current Treatment Indications § NMPA (China FDA) – Depression and Insomnia (Gen-2) § FDA – Anxiety and Insomnia (Gen-1), Depression (2003-2019) Innovative Digital Near-Term Growth Tele-Med Advantage Nexalin’s Gen-3 medical Nexalin will introduce at-home Treatment with devices i
Slide 7: Large and Growing Treatment Markets
Large and Growing Treatment Markets Everyone Likely Knows Someone That Needs Help >35% #1 Of reporting adults in the Depression is the leading $210.5 Billion US have experienced cause of disability in the Lost earnings per year due short sleep duration (< 7 US among ages 15-44.3 to serious mental il
Slide 8: The Nexalin Target Market – 6 of 10 will never receive treatment
The Nexalin Target Market – 6 of 10 will never receive treatment - Most people in need of mental health care will not receive it - those that do receive care, are usually given medication 58% <50% 75% of patients experience remission rate for of participants moderately severe the most common across
Slide 9: The Global Mental Health Epidemic
The Global Mental Health Epidemic Insomnia Anxiety Dementia and Depression Addiction Almost 40 million Americans Anxiety disorders are An estimated 6.2 million Approximately 20 million suffer from chronic insomnia common, affecting about 18 Americans aged 65 and older Americans battled some form (NC
Slide 10: The Industry Approach is Flawed
The Industry Approach is Flawed Current treatment options for common mental health illnesses present more obstacles than solutions for the patient Handheld - tDCS (internet) Pharmaceutical - Drugs & Pills Transcranial Magnetic • Low Efficacy Stimulation rTMS • Low Efficacy • Low Efficacy • Side Effe
Slide 11: Technology Improvements
Technology Improvements 2020 Q4 2021 Q2 2003 China A,D China A,D,I Nexalin Gen-1 Nexalin develops and begins China NMPA approves Nexalin for Clears FDA for the treatment of research on the China A,D treatment of Depression and Insomnia Anxiety, Depression and Insomnia device (Alzheimer's and Nexalin
Slide 12: Our Patented Technology
Our Patented Technology Features and Benefits • Low Risk Profile – 4/15 milliamps (safe) Nexalin uses proprietary single-use electrodes to deliver an undetectable proprietary frequency-based waveform • Non-Invasive (low ancillary needs) with lifetime recurring revenue. • 77.5 htz Frequency (propriet
Slide 13: The Virtual Clinic Model
The Virtual Clinic Model Nexalin has designed generation 2 & 3 models to allow patients to receive treatment in a clinic or from the comfort of their home with medical supervision. Physicians will be able to administer and monitor the patient's therapy and progress remotely through the planned Nexal
Slide 14: Benefit and Value of Virtual Clinic – Physician is Paid
Benefit and Value of Virtual Clinic – Physician is Paid Nexalin Technology: The virtual clinic allows Nexalin to promote the physician – patient relationship in the privacy of the home. Physicians can prescribe and monitor the treatment in patient portal . Physicians: Patients: The virtual model all
Slide 15: Future Treatments and Revenue Creation
Future Treatments and Revenue Creation Possible Future Treatment Indications: Revenue Creation: § Anxiety and Insomnia § Our Chinese distributor is currently selling § Depression Gen-2 Nexalin devices in China. § Substance Abuse Disorder (SUD) § The Company will sell the Nexalin device to § Concussi
Slide 16: Nexalin Global Strategy – China
Nexalin Global Strategy – China ü Establishing a Joint Venture to Limit Investment Risk ü All Chinese Marketing and Chinese Clinicals Fully Funded by China distributor ü China FDA (NMPA) application approved Q3 2021 • Depression and Insomnia at 15 mAmps (Gen-2) ü 2022 Sales Orders for 200 Nexalin De
Slide 17: Global Funded Clinical Trials in Process
Global Funded Clinical Trials in Process Drive acceptance through trials, key opinion leaders and direct sales 17
Slide 18: Recent Clinical Trial Results
Recent Clinical Trial Results Nexalin Technology providers report 75% of patients treated have over 70% improvement and 90% had over 50% improvement of their reported symptoms. 1 2 NEXALIN TECHNOLOGY CLINICS ANXIETY DEPRESSION INSOMNIA Diagnosed Average Improvement 77% 74% 84% 1. Insomnia Clinical T
Slide 19: Nexalin Financials
Nexalin Financials Nexalin Technology, Inc. and Subsidiary Condensed Consolidated Statements of Operations 1. All figures shown reflect a 20-1 reverse split completed December 2021 2. Selected financial information derived from the audited and unaudited financial statements and related notes contain
Slide 20: Nexalin Financials Cont.
Nexalin Financials Cont. Nexalin Technology, Inc. and Subsidiary Nexalin Technology, Inc. and Subsidiary Condensed Consolidated Balance Sheets Capitalization Table ($) As of September 30, As of December 31, Balance Sheet 2022 2021 Capitalization Table(1) As of September 30, 2022 Common stock, shares
Slide 21: Thank You
Thank You
Nexalin Technology — Investor Presentation (January 2023) on 6ix